NorthWest Biotherapeutics Inc (NWBO)

[Poor Man -]

That’s an interesting question, Margaret. There’s no conflicts related to pursuing multiple lines of drug discovery. Cost could obviously be a consideration.

But if Merck were to acquire D and enter into licensing or JVs with other BPs for various indications (See: Multiple BP attendees on Tuesday) then maybe conflicts of interest do enter into the equation as a concern by potential partners.

NWBO has normalized various types of conflicts of interest. But in the real world of large corporations, those are taken much more seriously, and could determine whether another party is actually willing to partner.

Tuesday morning in New York City, USA, 11:10pm EST is an inflection point.